Cipher Pharmaceuticals Stock Net Income
| CPHRFDelisted Stock | USD 2.57 0.00 0.00% |
Cipher Pharmaceuticals fundamentals help investors to digest information that contributes to Cipher Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Cipher OTC Stock. The fundamental analysis module provides a way to measure Cipher Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cipher Pharmaceuticals otc stock.
Cipher |
Cipher Pharmaceuticals OTC Stock Net Income Analysis
Cipher Pharmaceuticals' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Cipher Pharmaceuticals Net Income | 7.76 M |
Most of Cipher Pharmaceuticals' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cipher Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
CompetitionBased on the recorded statements, Cipher Pharmaceuticals reported net income of 7.76 M. This is 97.73% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The net income for all United States stocks is 98.64% higher than that of the company.
Cipher Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cipher Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Cipher Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Cipher Pharmaceuticals by comparing valuation metrics of similar companies.Cipher Pharmaceuticals is currently under evaluation in net income category among its peers.
Cipher Fundamentals
| Return On Equity | 0.24 | ||||
| Return On Asset | 0.15 | ||||
| Profit Margin | 0.45 % | ||||
| Operating Margin | 0.57 % | ||||
| Current Valuation | 46.13 M | ||||
| Shares Outstanding | 25.12 M | ||||
| Shares Owned By Insiders | 44.12 % | ||||
| Number Of Shares Shorted | 11.43 K | ||||
| Price To Earning | 15.54 X | ||||
| Price To Book | 1.63 X | ||||
| Price To Sales | 3.28 X | ||||
| Revenue | 21.94 M | ||||
| Gross Profit | 18.26 M | ||||
| EBITDA | 11.85 M | ||||
| Net Income | 7.76 M | ||||
| Cash And Equivalents | 24.19 M | ||||
| Cash Per Share | 0.96 X | ||||
| Total Debt | 507 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 2.51 X | ||||
| Book Value Per Share | 1.77 X | ||||
| Cash Flow From Operations | 13.81 M | ||||
| Short Ratio | 0.97 X | ||||
| Earnings Per Share | 0.36 X | ||||
| Target Price | 5.59 | ||||
| Number Of Employees | 26 | ||||
| Beta | 1.03 | ||||
| Market Capitalization | 64.32 M | ||||
| Total Asset | 51.65 M | ||||
| Z Score | 75.6 | ||||
| Net Asset | 51.65 M |
About Cipher Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cipher Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cipher Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cipher Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Other Consideration for investing in Cipher OTC Stock
If you are still planning to invest in Cipher Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Cipher Pharmaceuticals' history and understand the potential risks before investing.
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |